col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

BMJ: European Journal of Hospital Pharmacy
  original article Date Title Authors   All Authors
1 [GO] 2021―Jun―03 Benefit versus toxicity risk of digoxin in patients with COVID-19 Burcu Kelleci Cakir, Aygin Bayraktar-Ekincioglu, Kutay Demirkan
2 [GO] 2021―May―19 Treatment of high-risk bleeding with susoctocog alfa in a patient with acquired haemophilia A and a nosocomial severe acute respiratory syndrome coronavirus 2 infection Carla Fernández-Oliveira, Sandra Rotea-Salvo, Marta Fernández-Docampo, Sara González-Piñeiro, Isabel Martín-Herranz
3 [GO] 2021―May―14 Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19 Shaghayegh Mohsenian Naghani, Mark MPM Jansen, Tessa Jaspers, Diane Bastiaans, David Burger
4 [GO] 2021―May―14 SARS-CoV-2: an opportunity for hospital pharmacy Raquel Claramunt García, Carmen Lucía Muñoz-Cid, Andrés Sánchez Ruiz
5 [GO] 2021―Apr―23 The European coalition for vaccination calls on healthcare professionals to get vaccinated against COVID-19 Stephanie Kohl
6 [GO] 2021―Apr―14 Hospital pharmacy response to COVID-19 at two UK teaching hospitals: a departmental review of actions implemented to inform future strategy Jeff Aston, Inderjit Singh, Caroline Cheng, Aisling Considine
7 [GO] 2021―Apr―13 COVID-19 impact on skills and professional perceptions of the hospital pharmacist during the first outbreak wave Vera Damuzzo, Riccardo Bertin, Daniele Mengato, Marco Chiumente, Melania Rivano, Angelo Claudio Palozzo
8 [GO] 2021―Apr―13 Hand hygiene for healthcare workers: did we need COVID-19 to raise awareness of proper disinfection practice? Daniele Mengato, Lorenzo Di Spazio
9 [GO] 2021―Apr―08 Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19 Christian Skalafouris, Caroline Samer, Jerome Stirnemann, Olivier Grosgurin, François Eggimann, Damien Grauser, et al. (+3)
10 [GO] 2021―Mar―31 Managing the risk of shortages and medication errors with curares during the COVID-19 pandemic: a hospital pharmacy experience Xavier Bohand, Dominique Jordan, Frederique Dubois
11 [GO] 2021―Mar―11 Analysis of clinical pharmacist interventions in the COVID-19 units of a French university hospital Maxime Perez, Morgane Masse, Anne Deldicque, Jean Baptiste Beuscart, Pascal De Groote, Jacques Desbordes, et al. (+7)
12 [GO] 2021―Feb―24 Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19 Raquel Moreno Diaz, Miguel Angel Amor García, Francisco Javier Teigell Muñoz, Leonardo Ernesto Saldaña Perez, María Mateos Gonzalez, Jose Antonio Melero Bermejo, et al. (+5)
13 [GO] 2021―Feb―22 The European COVID-19 drugs calculation tool: an aid for the estimation of the drugs needed during the SARS-CoV 2 pandemic Daniele Leonardi Vinci, Adriano Meccio, Alessio Provenzani, Maria Ernestina Faggiano, Nenad Miljković, Despina Makridaki, et al. (+2)
14 [GO] 2021―Feb―19 EAHP opinion on COVID-19 vaccine programmes and their implementation Stephanie Kohl
15 [GO] 2021―Feb―19 Information on COVID-19 vaccines and vaccinations Stephanie Kohl
16 [GO] 2021―Feb―08 SARS-COV-2 pandemic: establishing three risk levels for 19 Italian regions and two autonomous provinces Andrea Messori, Manuela Angileri, Marco Chiumente, Laura Agnoletto, Paolo Baldo, Laura Bartoli, et al. (+8)
17 [GO] 2021―Feb―05 Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease Sabina Iluta, Sergiu Pasca, Delia Dima, Gabriela Mester, Laura Urian, Anca Bojan, et al. (+4)
18 [GO] 2021―Jan―27 Web searches for anxiolytic drugs during the COVID-19 outbreak in the USA Giuseppe Lippi, Brandon M Henry, Fabian Sanchis-Gomar
19 [GO] 2021―Jan―27 Is sitagliptin effective for the treatment of COVID-19? Hasan Memiş, Ahmet Çakır, Mefküre DURMUŞ, Selim GÖK, Ömer Faruk Bahçeciȯğlu
20 [GO] 2021―Jan―15 A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report Fátima Falcão, Erica Viegas, Ines Carmo, Joana Soares, Margarida Falcao, Mariana Solano, et al. (+14)
21 [GO] 2020―Dec―22 Some reflections on the current COVID-19 pandemic Philip Wiffen
22 [GO] 2020―Dec―22 Epinephrine use in COVID-19: friend or foe? Pan Luo, Dong Liu, Juan Li
23 [GO] 2020―Dec―05 Investigating the challenges and opportunities for medicines management in an NHS field hospital during the COVID-19 pandemic Jennifer de Val, Gurjit Sohal, Asif Sarwar, Haseeb Ahmed, Inderjit Singh, Jamie J Coleman
24 [GO] 2020―Nov―25 Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital Benedicte Gourieux, Fanny Reisz, Anne Sophie Belmas, François Danion, Marion Fourtage, Thierry Nai, et al. (+5)
25 [GO] 2020―Nov―20 Prescription profile in patients with SARS-CoV-2 infection hospitalised in Aragon, Spain Adriana Alvarez, Laura Cabia, Cristina Trigo, Ana Cristina Bandrés, María Bestué
26 [GO] 2020―Oct―28 Implementation of a novel home delivery service during pandemic Ana Peláez Bejarano, Pilar Villar Santos, Maria de las Aguas Robustillo-Cortés, Ernesto Sánchez Gómez, Maria Dolores Santos Rubio
27 [GO] 2020―Sep―10 Observational study on off-label use of tocilizumab in patients with severe COVID-19 Laetitia Albertini, Mickael Soletchnik, Anais Razurel, Johana Cohen, Frédéric Bidegain, Francis Fauvelle, et al. (+4)
28 [GO] 2020―Jul―31 Consistency of recommendations from clinical practice guidelines for the management of critically ill COVID-19 patients Chia Siang Kow, Toby Capstick, Syed Tabish Razi Zaidi, Syed Shahzad Hasan
29 [GO] 2020―Jul―13 Informing critical care drug requirements in response to the COVID-19 pandemic Anita Hogg, Rachel Huey, Michael G Scott, Andrew Ferguson
30 [GO] 2020―Jul―03 Do psychotropic drugs used during COVID-19 therapy have an effect on the treatment process? Nadir Yalçın, Sertaç Ak, Kutay Demirkan
31 [GO] 2020―Jun―10 Fighting on two fronts: drug-drug interactions in people living with HIV infected with SARS-CoV-2 Melda Bahap, Emre Kara, Gulay Sain Guven
32 [GO] 2020―Jun―04 Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19 Tomás Palanques-Pastor, Eduardo López-Briz, José Luis Poveda Andrés
33 [GO] 2020―May―26 Investigation on cognition of covid-19 and safety during the pandemic among hospital pharmacy staff Yan He, Wei Li, Dong Liu
34 [GO] 2020―Apr―23 EAHP launches COVID-19 resource centre for hospital pharmacists Stephanie Kohl
35 [GO] 2020―Mar―19 The healthcare and pharmaceutical vulnerability emerging from the new Coronavirus outbreak Daniele Leonardi, Carlo Polidori, Piera Polidori
36 [GO] 2020―Feb―21 Houston we have a problem: coronavirus! Philip Wiffen


[de][en]

Last change 2021―Jun―30 20:09:44 UTC

© Daten-Quadrat 2021       Done in 0.004 sec